Economics of pharmacogenetic guided treatments: Underwhelming or overstated?
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
Fersiynau electronig
Dogfennau
- 2018 Economics of pharmacogenetic
Llawysgrif awdur wedi’i dderbyn, 399 KB, dogfen-PDF
Dangosydd eitem ddigidol (DOI)
Economic evaluations have dispelled a perception that precision medicine, achieved through pharmacogenetic testing, reduces healthcare costs. For many tests aimed at preventing adverse drug reactions, cost‐effectiveness analyses predict modest improvements in health benefits and increases in total costs. While there are many uncertainties in estimating the value of testing, factors that influence cost‐effectiveness include the rarity of the outcome, the effectiveness of alternative treatments, and the scope and perspective of analysis.
| Iaith wreiddiol | Saesneg |
|---|---|
| Tudalennau (o-i) | 749-751 |
| Cyfnodolyn | Clinical Pharmacology and Therapeutics |
| Cyfrol | 103 |
| Rhif y cyfnodolyn | 5 |
| Dyddiad ar-lein cynnar | 13 Chwef 2018 |
| Dynodwyr Gwrthrych Digidol (DOIs) | |
| Statws | Cyhoeddwyd - Mai 2018 |
Cyfanswm lawlrlwytho
Nid oes data ar gael